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Abstract
Background: The selection of agents for any treatment regimen is in part influenced by physician
and patient attitudes. This study investigated attitudinal motivators and barriers to the use of self-
injectable antiretroviral agents among physicians and patients and measured the degree of
concordance between physician and patient perspectives.
Methods: Attitudes toward prescribing and usage of self-injectable antiretroviral therapy (SIAT)
were assessed by structured interview in 2 cohorts sampled from the European Union and the
USA: 499 HIV-treating physicians and 603 treatment-experienced HIV-infected patients.
Motivators and barriers to prescribing SIAT were identified from statistical analysis of the
associations between physicians' ratings of enfuvirtide-based therapy compared to standard oral-
based therapy and 2 indicators of enfuvirtide prescribing behavior. Patients' attitudes were assessed
by their responses to a written profile of enfuvirtide and their ratings of the likelihood of accepting
a treatment offer.
Results: Both indicators of SIAT prescribing behavior were predicted by the same pattern of
physician beliefs. Nonprescribing was associated with: (1) the belief that offering enfuvirtide would
be perceived negatively by patients, leading to treatment refusal and nonadherence; (2) the belief
that prescribing enfuvirtide is harder to justify in terms of time/resources; and (3) a lack of
confidence in the efficacy and use of enfuvirtide in practice (all p < 0.05). However, physicians'
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beliefs were not in concordance with patients' views. After reading a profile of enfuvirtide, 76%
patients said that they would be moderately or highly likely to accept a treatment offer, although
most (72%) had not discussed enfuvirtide with their doctor. Patients' beliefs predicted the
likelihood of accepting enfuvirtide.
Conclusion:  Physician and patient beliefs about SIAT influence prescribing behavior and
compliance yet may not be concordant, with patients having more positive attitudes towards SIAT
than anticipated by physicians.
Background
Although oral administration remains the most prevalent
method of administering pharmaceutical agents, an
increasing number of individuals depend on self-injecta-
ble medications for the effective treatment of their chronic
illnesses and conditions including diabetes, hepatitis C,
growth hormone deficiency, infertility, multiple sclerosis,
and HIV. Chronic self-injection of medicinal therapeutics
is associated with a number of potential drawbacks that
can influence acceptability, including fear of needles,
increased risk of disease disclosure, inconvenience, safety
issues (including sharps disposal), local ISRs, and in
many cases, the need for product reconstitution prior to
injection. These novel challenges for physicians and
patients can delay or prevent initiation of therapy – a phe-
nomenon previously reported for injectable insulin ther-
apy prescribed for patients with type 2 diabetes [1,2].
These issues are now salient in HIV therapy. Enfuvirtide is
the first approved HIV-fusion inhibitor and the first
approved antiretroviral (ARV) agent that cannot be
administered orally. Currently, it is formulated as a pow-
der to be reconstituted and injected subcutaneously.
Although enfuvirtide has demonstrated activity against
HIV-1 strains that are resistant to all 3 of the original ARV
drug classes [3], has a proven efficacy and safety profile [4-
7], and is cited by major HIV-treatment guidelines for use
in treatment-experienced patients [8-11], research sug-
gests that it is under-utilized in current clinical practice
[12].
The translation of novel health technologies, such as enfu-
virtide, into health gain for affected individuals is depend-
ent on the behavior of clinicians and patients. The
clinician needs to make an appropriate treatment recom-
mendation and the patient must be committed to adhere
to the appropriately prescribed treatment. Physician and
patient behavior and decisions about treatment are likely
to be influenced by both perceptual factors (eg, beliefs,
attitudes, and preferences) and practical factors (eg, capac-
ity and resources), as has been shown previously for the
management of heart failure [13].
Facilitating optimal patient management requires an
understanding of both the physician's and the patient's
perspectives of treatment and, in this situation, the chal-
lenges of prescribing and adhering to ARVs. Research into
patient adherence to ARVs has improved our understand-
ing of patient perspectives and has identified some of the
key factors influencing patient motivation and the ability
to initiate and to continue with treatment [14-16]. How-
ever, there are no recent studies that have considered phy-
sician perspectives on ARVs and thus we know little about
the perceptual and practical barriers to the optimal pre-
scribing of these drugs. The relatively low uptake of SIAT,
despite the available evidence supporting its efficacy and
safety, suggests that there is a need for a systematic study
of the barriers against and drivers for the use of such ther-
apies from both physician and patient perspectives.
Previous pilot qualitative research suggests there may be a
range of barriers influencing enfuvirtide prescribing and
uptake/acceptance and that some potentially important
disconnects may exist between physician and patient per-
ceptions of self-injectable treatment [17]. In order to iden-
tify, quantify, and compare physicians' and patients'
beliefs about self-injectable treatment and to examine the
relationship between their beliefs and SIAT use in clinical
practice, we conducted a large-scale empirical investiga-
tion of physician and patient perceptions self-injectable
treatment, using enfuvirtide as the treatment example.
The principal aims of our study were to understand the
underlying motivations for physicians to prescribe or not
to prescribe self-injectable treatment; to understand the
motivation behind treatment-experienced patients'
acceptance of enfuvirtide as a treatment; and to identify
potential incongruence between the perceptions of physi-
cians and their patients regarding self-injectable treatment
in HIV. This research should be useful in developing evi-
dence-based interventions to align treatment motivations
for both physicians and patients, which could have
broader applications in other therapeutic areas where self-
injection is needed.
Methods
Beliefs about SIAT were assessed by questionnaires
administered in structured interviews of physician and
patient cohorts in Germany, France, Italy, Spain, the UK,
and the USA between May and August 2005. The studyAIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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was comprised of 3 phases: (1) identification of potential
barriers and drivers to prescribing SIAT among a physician
cohort; (2) evaluation of attitudes, in a patient cohort,
toward enfuvirtide (using a written profile of the drug as a
basis), including patient willingness to accept a treatment
offer of enfuvirtide from their physician; and (3) a quali-
tative comparison between the perceptions identified for
physician and patient cohorts. The questionnaires were
designed by the study group of researchers and clinicians
on the basis of the results of an exploratory, qualitative
study [17]. Questionnaires were piloted in the UK and
then translated to the required languages. Participants
were reimbursed according to local guidelines and good
practice. All interviews were conducted by trained medical
interviewers and in accordance with the Data Protection
Act. Each participant was assured complete confidential-
ity.
Physician cohort
Enrolment procedure
Physicians at HIV centers and hospitals geographically
distributed across each country were initially approached
via telephone and screened for eligibility. Physicians were
eligible for the study if they were HIV- or infectious dis-
ease-specialists treating patients with HIV, had at least 3
years of experience prescribing ARVs, and claimed a min-
imum of 15% treatment-experienced patients within their
clinic. (In this study 'treatment-experienced patients' were
defined as patients who had been exposed to [but had not
necessarily failed therapy on] at least 8 different ARVs,
including those in their current regimen. These patients
are generally suitable candidates for enfuvirtide treatment
at their next treatment change, according to authoritative
HIV-treatment guidelines [8-11].)
Assessing physician attitudes to enfuvirtide and prescribing behavior
Physician beliefs about enfuvirtide were assessed on the
basis of their responses to 31 statements about an enfuvir-
tide-based regimen relative to a standard oral ARV-based
regimen. The belief statements represented potential bar-
riers against and drivers for the use of enfuvirtide for treat-
ment-experienced patients that had been previously
identified in a qualitative study [17]. Physicians rated
their level of agreement with each of the belief statements
on a 7-point Likert-scale (where 1 = strongly disagree, 7 =
strongly agree, and 4 = neutral). Responses were subjected
to principal components analysis (PCA), transforming
group beliefs into core themes or factors.
Physician prescribing behavior
1. Physicians' reports of their current enfuvirtide prescribing levels
On the basis of their responses, physicians were classified
into 3 different prescriber categories: 'nonprescribers': 0
patients prescribed enfuvirtide; 'lower prescribers': 1–4
patients prescribed enfuvirtide; and 'higher prescribers': =
5 patients prescribed enfuvirtide.
2. Prescribing intentions in case scenarios
Physicians evaluated 2 hypothetical patient case scenarios
– one of a former IVD user and the other of a patient with
a history of nonadherence. The patient-case scenarios gen-
erated by an international expert HIV physician panel
were to include clear candidates for enfuvirtide, as indi-
cated by international guidelines [8-10]. Physicians were
asked to choose between 2 treatment options, one of
which included enfuvirtide (Table 1). A similar approach
has been used in previous studies investigating physician
prescribing behavior [13].
Patient cohort
The patient enrolment procedure was approved by the
European Community Advisory Board, a recognized inter-
national AIDS patient organization and one the 3 working
groups of the European AIDS Treatment Group. Eligible
patients were at least 16 years of age, treatment experi-
enced (according to the study definition), and currently
receiving ARV therapy. Patients were primarily identified
by individuals enrolled in the physician cohort, who were
asked to establish whether the next 2 treatment-experi-
enced patients seen would be willing to participate in a
telephone research interview. If a patient refused, physi-
cians were asked to approach subsequent treatment-expe-
rienced patients until 2 candidates had been identified.
Additional patients were recruited through nonstudy phy-
sicians, nurses, patient organizations, and, in the UK and
Spain, through posters advertising the study in general
practitioners' offices and patient organizations (using a
'freephone' contact number). Standard consent proce-
dures were followed.
Assessing patient attitudes toward SIAT
Structured interviews (approximately 30 minutes) were
conducted by telephone (except in Italy where, due to
data protection laws, the interviews were conducted face-
to-face). Patients rated their level of agreement with a
series of 29 attitudinal statements representing potential
barriers and motivators to using SIAT that were derived
from previous qualitative research [17]. Responses were
scored on a 7-point Likert-style scale, where 1 = 'strongly
disagree', 7 = 'strongly agree', and 4 = neutral. Participants
were shown a written profile describing enfuvirtide (avail-
able on request from the authors) and were asked a range
of questions regarding the product's level of appeal and
acceptability. Those not currently taking enfuvirtide were
asked to rate on a 7-point scale (where 1 indicated 'not
likely at all' and 7 indicated 'very likely') their likelihood
of accepting this drug. Responses were used to group
patients into 3 categories: unlikely to accept (responsesAIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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between 1–3); moderately likely to accept (responses of
4); or likely to accept (responses between 5–7).
Statistical methods
Target sample sizes were chosen to be representative of
each country. The overall sample size was selected to
allow for 90% confidence that error would be within ±
10%. Our overall target was 510 physicians (75 physicians
each from France, Italy, Spain, and the UK, 60 from Ger-
many, and 150 from the USA) and 650 patients (100
patients each from France, Germany, Italy, Spain, and the
UK, and 150 from the USA).
Data were analyzed using Statistical Package for the Social
Sciences (SPSS® 12.0, SPSS Inc, Chicago, Illinois) software.
Associations between physician characteristics and pre-
scriber category were explored using the chi-square test for
categorical variables and 1-way ANOVA with Tukey's post-
hoc comparison tests for continuous variables.
Principal components analysis (PCA) with varimax rota-
tion was used to identify the main themes (factors) under-
pinning physicians' and patients' attitudes to SIAT. Items
with low values on the Keiser Meyer Olkin (KMO) meas-
ure of sampling adequacy were excluded. The internal reli-
ability of the resulting measure of each theme was
assessed using Cronbach's alpha. A value of ≥ 0.6 was con-
sidered acceptable for this exploratory study.
Logistic regression was used to calculate odds ratios and
95% confidence intervals for the relationship between
physician beliefs and the likelihood of prescribing a SIAT
(according to current enfuvirtide prescribing rates and
choice of regimen in the case scenarios), controlling for
demographic characteristics (number of HIV patients
managed and country). Continuous predictor variables
were dichotomized at the median value to aid interpreta-
tion of the odds ratio.
One-way ANOVA, with Tukey's post-hoc comparison tests
was used to explore the association between a patient's
beliefs and their stated likelihood of accepting an offer of
enfuvirtide from their physician. A p value of < 0.05, using
a 2-tailed analysis, was considered significant.
Results
Physician cohort
Participants
Of 948 physicians approached, 191 did not meet eligibil-
ity criteria and 258 study-eligible physicians declined to
participate, resulting in a final sample size of 499 physi-
cians. Table 2 summarizes their demographic and practice
characteristics.
Physician beliefs about enfuvirtide
PCA of physicians' responses to the 31 belief statements
about an enfuvirtide-based vs a standard oral-based ARV
regimen identified 7 factors or 'themes'. The individual
belief statements loading on each of the 7 factors are avail-
able on request. The Cronbach's alpha values indicate that
6 of the 7 scales had an acceptable internal reliability.
Physician prescribing intentions and behaviour
1. Enfuvirtide-prescribing rates
120 physicians (24%) were classified as 'nonprescribers',
204 (41%) were 'lower prescribers,' and 175 (35%) were
Table 1: Summary of case scenarios
Two scenarios were used to evaluated physicians' prescribing intent for patients who are clear candidates for receiving a new ARV class to 
achieve treatment goals as recommended by international guidelines
Case 1: Ex-IVD user
• 46-Year-old white heterosexual male infected with HIV through IVD use and diagnosed in 1989
￿ Peak VL 100 000 copies/mL, CD4 nadir 40 cells/mm3; current VL 20 000 copies/mL, CD4 145 cells/mm3 (declined 30 cells/mm3 since previous visit)
￿ Treatment history includes ZDV, d4T, ddI, ddC, EFV, NVP, SQV, IDV, SQV/r, NFV, LPV/r, and IDV/r 
(severe reactions with NNRTIs and developed K103N mutation; gastrointestinal distress with many PIs, particularly LPV/r; patient also suffers from severe 
lipodystrophy)
Two regimen options recommended by HIV physician panel:
￿ Option X: TPV/r + enfuvirtide + 3TC + TDF
￿ Option P: ATV/r/SQV + 3TC + TDF
Case 2: Patient with history of nonadherence
￿ 42-Year-old black African female diagnosed with AIDS (pneumocystis pneumonia) in 2002
￿ At diagnosis, VL 100 000 copies/mL and CD4 40 cells/mm3; current VL 2000 copies/mL and CD4 200 cells/mm3 (210 cells/mm3 at previous visit)
￿ Treatment history includes ZDV, ABC, TDF, 3TC, FTC, EFV, ATV/r, and LPV/r
￿ Resistance profile includes 41L, 215Y, 184V, and 103N
￿ Nonadherence associated with gastrointestinal side effects, failure to take drugs on days that patient feels healthy and running out of drugs during an 
extended trip to Africa
Two regimen options recommended by HIV physician panel:
￿ Option X: TPV/r + enfuvirtide + 3TC + TDF
￿ Option P: FPV/r/SQV + 3TC + TDFAIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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'higher prescribers' (Table 2). The proportion of physi-
cians who were higher prescribers differed by country (χ2
(5) 24.79, p < 0.001). Those based in Germany were more
likely to be higher prescribers (χ2 [1] 6.93, p < 0.01), while
those based in the UK were less likely to be higher pre-
scribers (χ2 [1] 17.58, p < 0.001). Physicians who were cat-
egorized as 'higher prescribers' personally managed a
greater number of patients with HIV (χ2 [2] 54.81, p <
0.001) than did lower and nonprescribers of enfuvirtide.
When physicians were asked to rate their experience of
prescribing self-injectable therapy for any condition, there
were significant differences between the 3 prescriber cate-
gories (F [2498] = 7.87, p < 0.001). Higher prescribers
indicated a greater level of experience than both lower (p
< 0.05) and nonprescribers (p < 0.001). Higher prescrib-
ers also were more likely to take part in clinical trials/
research (χ2 [2] = 17.58, p < 0.001) and author papers
about the management of HIV (χ2 [2] = 9.20, p < 0.005)
than were lower and nonprescribers.
Physician beliefs associated with enfuvirtide-prescribing intentions 
and behavior
Table 3 shows the multivariate odds ratios (95% confi-
dence intervals) for physician beliefs influencing enfuvir-
tide-prescribing intention and behavior. A similar pattern
of physician beliefs about SIAT predicted both prescribing
indicators. Four attitudinal factors were particularly influ-
ential in terms of enfuvirtide prescribing.
Low rates of enfuvirtide prescribing in practice were asso-
ciated with a:
- Lack of personal confidence in the efficacy of enfuvirtide
and its use in practice
Table 2: Demographics and practice characteristics of physician sample; n (%) unless otherwise stated
Nonprescribera
(0 patients)
Lower prescribera
(1–4 patients)
Higher prescribera
(≥ 5 patients)
Total
Physicians 120 (24) 204 (41) 175 (35) 499 (100)
Physicians with missing data (excluded from analysis) 8 (7) 2 (1) 1 (1) 11 (2)
Years practicing as an HIV-related physician, median (range) 12.4 (3–30) 11.8 (3–31) 11.5 3–30) 11.0 (3–31)
Medical specialty
HIV/AIDS specialist 58 (52) 113 (56) 87 (50) 258 (53)
ID specialist 41 (37) 73 (36) 69 (40) 183 (38)
Otherb 9 (8) 10 (5) 11 (6) 30 (6)
Base
Hospital 88 (79) 140 (69) 123 (71) 351 (72)
Office 24 (21) 62 (31) 50 (29) 136 (28)
Patients with HIV currently managed
 100 49 (44) 36 (18) 11 (6) 96 (20)
101–300 57 (51) 137 (68) 112 (64) 306 (63)
301+ 6 (5) 29 (14) 51 (29) 86 (18)
Proportion of these patients who are treatment experiencedc
< 10%d 4 (4) 8 (4) 1 (1) 13 (3)
10% to 24% 49 (44) 93 (46) 62 (36) 204 (42)
25% to 49% 41 (37) 60 (30) 74 (43) 175 (36)
50% to 74% 13 (12) 33 (16) 28 (16) 74 (15)
 75% 5 (5) 8 (4) 9 (5) 22 (4)
Country
UK 31 (28) 23 (11) 7 (4) 61e (13)
France 9 (8) 38 (19) 28 (16) 75 (15)
Germany 10 (9) 17 (8) 31 (18) 58 (12)
Spain 14 (13) 39 (19) 21 (12) 74 (15)
Italy 18 (16) 25 (12) 32 (18) 75 (15)
USA 30 (27) 60 (30) 55 (31) 145 (30)
Percentages may not total 100 because of rounding.
aBased on the number of patients currently prescribed enfuvirtide.
bGP/FP/IM specialist/PCP.
cDefined as patients who had been exposed to (but who had not necessarily failed therapy with) at least 8 different ARVs, including those in their 
current regimen.
dAt screening, these physicians stated that they had ≥ 15% treatment-experienced patients within their clinic and so were eligible to participate in 
the study.
eIn the course of fieldwork it was decided by the study team to reduce the number of physicians to be interviewed in the UK from 75 to 62, to 
represent a smaller physician population in this country.AIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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- Belief that enfuvirtide is associated with patient treat-
ment-refusal and nonadherence
- Belief that an enfuvirtide prescription is difficult to jus-
tify in terms of time and resources
- Belief that a treatment offer of enfuvirtide is likely to
jeopardize a patient's trust
2. Prescribing intentions in the case scenarios
In case 1 (ex-IVD user), 66% of physicians overall chose
to use enfuvirtide, while only 45% of physicians chose
enfuvirtide for a patient with a history of nonadherence to
ARVs (case 2). The beliefs associated with choosing enfu-
virtide for each case scenario are shown in Table 3.
Patient cohort
Of the 1314 patients approached, 273 did not meet eligi-
bility criteria and 439 study-eligible patients declined to
participate, resulting in a study cohort of 603 patients.
Table 4 summarizes their demographic characteristics.
Current use of enfuvirtide
Of the 603 interviewed patients, 61 (10%) were currently
receiving enfuvirtide. Of the 542 patients who were not
currently receiving enfuvirtide (categorized as 'nonusers'),
150 (28%) had discussed SIAT with their physician,
resulting in an offer of enfuvirtide therapy from their phy-
sician in 56 cases (37%). Among nonusers who had been
offered enfuvirtide, 17/56 (30%) had initiated therapy,
but subsequently discontinued treatment.
Likelihood of accepting enfuvirtide if offered by physician
After reviewing the description of enfuvirtide, 180 of the
516 patients who responded (35%) indicated that they
would be likely to accept this product if offered to them
by their physician (score 5–7), 214 (41%) would be mod-
erately likely to accept (score = 4), and 122 (24%) would
be unlikely to accept (score = 1–3).
Patients' beliefs about SIAT
The 3 most prevalent PCA-derived core beliefs were that
their doctor had positive views about self-injectable ther-
apies (52%), that SIAT would be effective and preferable
to other treatment options (35%), and that there would
be barriers to using SIAT (27%).
Predictors of likelihood of accepting enfuvirtide if offered by physician
Patients who indicated they were likely to accept therapy
were more likely to believe that SIAT is effective and pref-
erable to other treatment options (Table 5). In contrast,
patients who indicated that they were unlikely to accept
Table 3: Multivariate odds ratios (95% confidence intervals) for physicians' beliefs about enfuvirtide regimens compared with standard 
oral-based regimens for treatment-experienced patientsa
Physician belief themes Enfuvirtide-prescriber category Case scenarios
'Higher' (≥ 5 patients currently 
prescribed)b
(n = 175)
'Non' (no patients currently 
prescribed)c
(n = 120)
Physicians selecting enfuvirtide option
Case 1d
(n = 323)
Case 2e
(n = 214)
Personal confidence in the efficacy of 
enfuvirtide and its use in practice
3.35¶ 
(2.20, 5.08)
0.32¶ 
(0.19, 0.53)
2.44¶ 
(1.62, 3.66)
2.10‡ 
(1.44, 3.07)
Enfuvirtide is associated with treatment 
refusal and nonadherence
NS 2.05‡ 
(1.29, 3.25)
0.59† 
(0.40, 0.86)
0.69* 
(0.47, 0.99)
Enfuvirtide is difficult to justify in terms of 
time and resources
0.63* 
(0.42, 0.94)
1.69* 
(1.07, 2.64)
0.57‡ 
(0.39, 0.83)
NS
An enfuvirtide treatment offer is likely to 
jeopardize patients' trust
0.56‡ 
(0.37, 0.83)
1.86† 
(1.19, 2.92)
NS NS
Patients are likely to perceive that 
drawbacks of enfuvirtide outweigh its 
benefits
NS NS NS NS
Concerns about the risks of self-
injectable therapies
NS NS 0.52¶ 
(0.37, 0.78)
NS
Enfuvirtide is more suitable for 
nonadherent/chaotic patients
NS NS NS 2.44¶ 
(1.67, 3.57)
aControlling for number of patients with HIV managed by each physician and for country.
For the statistical comparisons:
bCompared with lower and nonprescribers.
cCompared with higher and lower prescribers.
dCompared with physicians who did not select the enfuvirtide option.
eCompared with physicians of patients who were currently prescribed enfuvirtide.
*p < 0.05; †p < 0.01; ‡p < 0.005, ¶p < 0.001.
NS = no statistically significant difference between comparators.AIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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enfuvirtide were more likely to perceive barriers to adher-
ing to SIAT, to have concerns about self-injecting, and
resistance to their doctor recommending SIAT although,
interestingly, the mean scores for these last 2 beliefs
among this patient subset were below the midpoint, indi-
cating modest overall disagreement with these beliefs.
Comparison of attitudes and beliefs between physician 
and patient cohorts
A number of interesting contrasts can be drawn from the
findings of the physican and patient cohorts. Although
76% of physicians had greater confidence in the efficacy
and clinical use of SIAT vs oral ARVs for treatment-experi-
enced patients, only 35% of patients perceived that SIAT
would be efficacious and preferable to other treatments.
However, while 40% of physicians felt that patients' per-
ceived drawbacks of enfuvirtide outweighed its benefits,
fewer than 1 in 3 patients agreed with this opinion.
Further, nearly half of all interviewed physicians believed
that enfuvirtide is associated with increased nonadher-
ence and treatment refusal, whereas only 27% of patients
agreed that there were perceived barriers to adherence
with self-injectable therapy, and just 24% indicated they
would resist enfuvirtide therapy if their physician recom-
mended it. Finally, a small number of physicians (8%)
reported that prescribing an enfuvirtide-based regimen
would be more likely than an oral ARV-based regimen to
jeopardize their patient's trust in them, whereas 15% of
patients indicated that a strong recommendation of a SIAT
by their doctor would damage the relationship between
them.
Discussion
In this large-scale empirical study we identified and quan-
tified the experiences, perceptions, and beliefs of physi-
cians and patients about SIAT, and examined the
relationship between their beliefs and its acceptance and
use in clinical practice. The findings suggest that, even
when SIAT is likely to be optimal for therapeutic success,
there are multiple physician and patient factors influenc-
ing whether a SIAT is prescribed to eligible patients, and
whether eligible patients are likely to comply with a SIAT.
Our findings indicate that current use of enfuvirtide in the
management of HIV infection is determined not only on
the basis of scientific evidence but also by physician expe-
riences and attitudes toward self-injectable therapy.
Higher enfuvirtide prescribers had a more positive view
about its efficacy, were more confident that prescribing
SIAT would not jeopardize their patients' trust and were
less likely to believe that prescribing SIAT would be diffi-
cult to justify in terms of time and resources. Differences
in beliefs of this type also were apparent between physi-
cians who selected the enfuvirtide option in the two case
scenarios vs those who did not. The fact that our findings
were consistent across the 2 prescribing outcomes further
supports validity.
Physicians who managed a greater number of patients
receiving enfuvirtide also managed more patients with
HIV overall and had more experience with prescribing
self-injectable therapies for other conditions. These find-
ings corroborate those of other studies showing that a lack
of physician experience with self-injectable therapy is a
barrier to prescribing self-injected medications [18].
The patients we studied would generally benefit from and
be eligible for an enfuvirtide-containing regimen at their
next treatment change, according to HIV treatment guide-
lines in use at the time of data collection [8-11]. Interest-
ingly, relatively few patients who currently were not
taking enfuvirtide had even discussed this treatment
option with their doctor. However, if patients had been
stable and virologically suppressed on their current regi-
Table 4: Characteristics of interviewed patients (n = 603)
n (%)
Gender
Male 437 (72)
Female 166 (28)
Age (years)
16–25 5 (1)
26–35 76 (13)
36–45 317 (53)
46–55 163 (27)
≥ 56 42 (7)
Country
UK 50 (8)
France 100 (17)
Germany 101 (17)
Spain 101 (17)
Italy 101 (17)
USA 150 (25)
Route of infection
Homosexual contact 212 (35)
Heterosexual contact 172 (29)
IVD use 138 (23)
Other 81 (13)
Education
Some high school/secondary school 161 (27)
Graduated high school/secondary school 174 (29)
Some college training 146 (24)
Graduated college/university 77 (13)
Completed postgraduate degree 18 (3)
Employment
Employed 218 (36)
Homemaker 17 (3)
Student 11 (2)
Retired 68 (11)
Unemployment benefit 148 (25)
Incapacity benefit 134 (22)AIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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men (a parameter that we did not measure), then the per-
ceived need for such a discussion would be low. After
viewing the product profile for enfuvirtide, more than
75% of patients said they would be at least moderately
likely to accept this therapy if offered to them by their
physician. Patients who were likely to accept such an offer
were more likely to believe that SIAT is efficacious and
preferable to other treatment options, and were less in
agreement with beliefs associated with perceived barriers
to adhering to SIAT, concerns about self-injecting, and
resistance to their doctor recommending self-injectable
therapy.
Perhaps the most interesting aspect of this study was the
finding that physicians specializing in HIV appeared to
have somewhat different perceptions about SIAT than did
treatment-experienced patients. Nearly half of all inter-
viewed physicians felt that enfuvirtide was associated with
increased nonadherence and treatment refusal, whereas
only 27% of patients agreed with perceived barriers to
adherence, and only 24% indicated they would resist this
type of therapy if recommended by their physician. Our
results suggest that patients' perceptions of SIAT may be
more positive than previously thought and patients may
be more receptive to initiating SIAT than currently
believed by physicians who manage patients with HIV.
We acknowledge study limitations associated with self-
reporting, self-presentation, and recall bias inherent in
research of this nature. However, we attempted to mini-
mize this potential bias by introducing our survey in a
neutral manner with the assurance of complete confiden-
tiality. Questions also were posed in a neutral manner,
participants only had to agree/disagree with statements
attributed to other physicians/patients, and a combina-
tion of both positive and negative statements was
included.
For the physician cohort analysis, our classification of
physicians as 'higher' vs 'lower' prescribers does not take
into account the number of triple-class-experienced
patients under their care, so may not accurately reflect
their true propensity to prescribe enfuvirtide to eligible
patients. It also does not take into account what resources,
supportive of enfuvirtide prescribing, were available to
individual physicians. It could be hypothesized that
higher prescribers were, for example, supported by a
broader multidisciplinary team of health care profession-
als than were lower prescribers or nonprescribers, thus
permitting a higher level of support in encouraging
patients to persist with injectable therapy.
Since subjects in the patient cohort were mainly referred
to the study by their HIV clinician, our sample may be
biased towards those with positive attitudes towards the
medical profession or research. Further bias may have
been introduced by the enfuvirtide profile, as some
patients may not have fully understood its contents, thus
compromising their ability to make informed choices.
Finally, Cronbach's alphas were relatively small (all but
one within the range 0.6–0.8). However, a value of 0.7 is
generally thought to be an acceptable reliability coeffi-
cient, while 0.6 is considered acceptable for an explora-
tory study [19,20].
We did not collect information on viral load. Attitudes
towards SIAT may differ between those who are sup-
pressed on their current therapy and those for whom a
change in therapy might be indicated. Research in other
conditions suggests that barriers to self-injecting are lower
among people who perceive their individual need for a
specific treatment to be high [21].
Since this study was conducted, several new agents have
been licensed for the treatment of ARV-experienced
Table 5: Beliefs influencing patients' likelihood of accepting enfuvirtide if offered to them by their physician
Likelihood of accepting enfuvirtide
Likelya Moderately likelyb Unlikelyc
(n = 180) (n = 214) (n = 122)
Mean (SD) Mean (SD) Mean (SD)
Perception that enfuvirtide is more effective and preferable to oral therapy 
(F [2502] = 102.5, p < 0.001)
4.39 (1.26) 3.34 (1.08) 2.53 (0.91)
Perceived barriers to adherence
(F [2503] = 77.26, p < 0.001)
2.45 (1.20) 3.52 (1.27) 4.27 (1.37)
Concerns about self injecting 
(F [2513] = 36.0, p < 0.001)
2.65 (1.14)* 3.29 (1.08)* 3.74 (1.18)
Resistance to doctor recommending self-injectable therapies
(F [2513] = 72.2, p < 0.001)
1.90 (1.12) 2.95 (1.35) 3.76 (1.61)
Perception that doctors have positive views about enfuvirtide
(F [2233] = 8.66, p < 0.001)
1.57 (0.50) 1.35 (0.48) 1.23 (0.42)
a, b, c: refer to the product profile (Figure 1) preference score. Patients responded to the question, "If you were offered this product by your 
physician, how likely would you be to accept it?" using ratings of a1–3, b4, and c5–7 on a 7-point scale, where 1 is 'very likely', 4 is a neutral opinion, 
and 7 is 'not likely at all.'
All comparisons p < 0.001 except for *p < 0.005.AIDS Research and Therapy 2009, 6:2 http://www.aidsrestherapy.com/content/6/1/2
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patients. These include new classes of drugs including
CCR5-inhibitors and integrase inhibitors as well as a new
potent protease inhibitor. As HIV physicians now have
more options available for the treatment of ARV-experi-
enced patients, the results of this study may now be appli-
cable to a smaller group of treatment-experienced
patients. However, the finding that treatment-experienced
patients' attitudes towards SIAT may be more positive
than their physicians anticipate suggests that discussions
about treatment options should not exclude self-injecta-
ble treatments on the basis of presumptions about
patients' negative attitudes towards them.
The findings of this study are comparable to those in other
long-term conditions such as diabetes and oesteoporosis,
where patients' views about self-injectable medications
were important determinants of their treatment decisions
[21-24]. They also support earlier research that suggests
physicians who manage patients with HIV and treatment-
experienced patients may have different perceptions
about SIAT [17]. Certainly in other therapeutic areas,
including asthma and oncology, physician-patient differ-
ences in the perception of self-injectable therapies have
been identified as having a range of adverse implications,
including a potential contribution to suboptimal patient
care [25-27]. While we have no direct evidence that enfu-
virtide is not being prescribed according to guidelines,
other research certainly suggests that this is the case [12].
Understanding both patient and physician perceptions is
a first step in designing evidence-based interventions to
facilitate the optimum use of SIAT in treatment-experi-
enced patients with HIV. Our findings suggest that more
needs to be done to integrate evidence-based physician-
oriented interventions within medical education pro-
grams to ensure that all physicians make informed treat-
ment decisions in conjunction with their patients when
prescribing a SIAT.
Conclusion
Our data indicate that, for SIAT, treatment decisions are
strongly linked to the personal perceptions and beliefs of
both physicians and patients. The results of this study
involving enfuvirtide provide an important insight into
the psychology behind the use of self- injectable therapy
and our findings potentially have implications across a
range of therapeutic areas in which parenteral administra-
tion of new medicines may be optimal for selected patient
populations. The relevance of SIAT is likely to grow given
the number of parenterally administered antiretrovirals
representing novel mechanistic classes that are currently
in clinical development.
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